Efficacy of Repeating Pulmonary Rehabilitation in People with COPD: A Systematic Review

Angela T Burge 1–3, Carla Malaguti 1,4, Mariana Hoffman 1, Alan Shiell 5, Christine F McDonald 3,6,7, David J Berlowitz 3,6,7, Anne E Holland 1–3

1Respiratory Research @ Alfred, Central Clinical School, Monash University, Melbourne, VIC, Australia; 2Physiotherapy Department, Alfred Health, Melbourne, VIC, Australia; 3Institute for Breathing and Sleep, Heidelberg, VIC, Australia; 4Faculty of Physiotherapy, Federal University of Juiz de Fora, Juiz de Fora, Brazil; 5Department of Public Health, La Trobe University, Bundoora, VIC, Australia; 6Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, VIC, Australia; 7Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia

Background: Pulmonary rehabilitation is an effective intervention for people with chronic obstructive pulmonary disease (COPD). People with COPD undertake repeat programs, but synthesis of evidence regarding such practice has not been undertaken. The aim of this systematic review was to establish the effects of repeating pulmonary rehabilitation subsequent to an initial program in people with COPD.

Methods: Studies where participants with COPD undertook >1 pulmonary rehabilitation program were included, incorporating RCT (randomized controlled trial) and non-randomized studies. Electronic database searches were undertaken. Two authors independently undertook study identification, data extraction and risk of bias assessment. The primary outcome was health-related quality of life (HRQoL); secondary outcomes were exercise capacity, hospitalizations and exacerbations, adherence, mortality and adverse events. Narrative synthesis was undertaken for clinically heterogeneous trials. Data from RCTs and non-randomized studies were not combined for analysis.

Results: Ten included studies (2 RCTs) involved 907 participants with COPD (n=653 had undertaken >1 program). The majority of studies were at high risk of bias. One RCT (n=33) reported no difference in HRQoL after a repeat program vs usual care following exacerbation (Chronic Respiratory Disease Questionnaire dyspnea domain score MD 0.4, 95% CI −0.5 to 3). In stable patients, clinically important and statistically significant improvements in HRQoL and exercise capacity were reported after repeat programs, but of a smaller magnitude than initial programs. There was evidence for reductions in exacerbations and hospitalizations, and shorter hospital length of stay for patients who repeated a program twice in 12 months compared to those who repeated once. No data for mortality or adverse events were available.

Conclusion: This systematic review provides limited evidence for benefits of repeating pulmonary rehabilitation in people with COPD, including improved HRQoL and exercise capacity, and reduced hospitalizations. However, most studies have high risk of bias, which reduces the certainty of these conclusions.

Study Registration: PROSPERO (CRD42020215093).

Keywords: COPD, repeat pulmonary rehabilitation, systematic review

Introduction

Pulmonary rehabilitation is an effective intervention for people with chronic obstructive pulmonary disease (COPD) that is recommended in clinical guidelines worldwide.1 Outpatient group programs commonly run twice a week for 7–8 weeks and encompass comprehensive assessment followed by patient-tailored therapies including exercise training, education and behavior change.2 Level 1 evidence shows improvements in exercise capacity and symptoms3 with a reduction in hospitalizations and length of stay in the 12 months following program completion.4,5

It is well documented that the initial beneficial effects diminish over time following pulmonary rehabilitation2,6 and that there is scant evidence for the efficacy of current models of maintenance programs.7 In clinical practice, it is not uncommon for people with COPD to be re-referred to pulmonary rehabilitation on more than one occasion and international guidelines/statement acknowledge that additional pulmonary rehabilitation programs at some time following the initial program may
provide further benefits. The timing of a repeat course of pulmonary rehabilitation may be prompted by a gradual decline in function or a rapid deterioration, such as may occur following an acute exacerbation of COPD. There have been calls for more information regarding the clinical benefits of repeat courses of pulmonary rehabilitation and recommendations regarding frequency, but synthesis of the available evidence to inform this practice has not been undertaken.

The aim of this systematic review is to establish the effects of repeating pulmonary rehabilitation subsequent to an initial program in people with COPD.

Methods
This systematic review was prospectively registered on PROSPERO (19 October 2020, CRD42020215093) and is presented according to the PRISMA guidelines.

Studies, Participants and Intervention
Studies where participants with COPD undertook a pulmonary rehabilitation program on more than one occasion were included, incorporating randomized controlled trials (RCTs) and non-randomized studies. A control group was not required for inclusion. Data for adults (18 years of age and over) with a diagnosis of COPD according to established criteria were included, regardless of disease severity.

All participants must have undertaken an initial pulmonary rehabilitation program of defined duration that included a component of physical rehabilitation incorporating whole-body exercise training (with or without resistance training) with or without any form of education and/or psychological support. The repeat pulmonary rehabilitation program was in accordance with the definition for the initial intervention and undertaken at any time point after completion of an initial pulmonary rehabilitation program. Studies involving maintenance programs were excluded, where exercise training was delivered at a lower dose than the initial program and/or was an indefinite/ongoing program. This was to ensure that any repeat program was delivered according to the same model and dose as the initial program. Studies not published in English were excluded.

Outcome Measures
The primary outcome was disease-specific health-related quality of life as measured with tools, eg, Chronic Respiratory Disease Questionnaire (CRQ, higher score = improvement), St George’s Respiratory Questionnaire (SGRQ, lower score = improvement). Secondary outcome measures were exercise capacity, hospitalization, mortality, adverse events and adherence. Measures of exercise capacity could reflect maximal capacity, peak capacity or functional exercise capacity measured by field walking tests including the 6-minute walk test (6MWT) or incremental shuttle walk test (ISWT). Where possible, the measure of effect was change from baseline value (post-program value – pre-program value). Post-program values were used if change values were not reported.

Search methods for Identification of Studies
Electronic searches of the following databases were undertaken: Cochrane Database of Systematic Reviews; MEDLINE; Embase; CINAHL (Cumulative Index to Nursing and Allied Health Literature); CENTRAL (Cochrane Central Register of Controlled Trials) and PEDro (Physiotherapy Evidence Database) (Supplemental Tables 1 and 2). Reference lists of included articles were reviewed. There were no limits on publication date prior to search execution on January 27, 2022 (English language only). Two co-authors (AB, MH) independently screened titles and abstracts, retrieved full-text publications and identified studies for inclusion. Discrepancies were resolved in consultation with a third co-author (AH).

Data Collection
Two co-authors (AB, CM) undertook independent data extraction including study characteristics (location and dates of data collection, design, inclusion and exclusion criteria, assessment timepoints), program features, participant characteristics and outcome data. Discrepancies were resolved in consultation with a third co-author (AH). Where necessary, data were extracted from published figures using https://automeris.io/WebPlotDigitizer/.
Assessment of Risk of Bias

Two co-authors (AB, CM) independently assessed risks of bias for each included RCT using the Cochrane Risk of Bias Tool.\textsuperscript{12} Discrepancies were resolved in consultation with a third co-author (AH). We assessed risks of bias according to the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective outcome reporting; and other potential bias. Overall risk of bias was then determined for each study (low: all adequate; moderate: 1 inadequate or 2 unclear; high: >1 inadequate or >2 unclear).\textsuperscript{12}

Risk of bias was assessed for non-randomized studies using the Standard Quality Assessment Criteria.\textsuperscript{13} These criteria incorporate study design, participant selection, allocation and blinding procedures, outcome measures, sample size, estimates of variance, confounding, reporting of results and evidence to support the conclusions. Each of 14 questions is scored according to criteria met (yes: 2 points; partial: 1 point; no: 0 points; N/A). The maximum score possible is 28, with scoring for each study calculated as a proportion of maximum possible accounting for the number of N/A items (28 minus [number of N/A × 2]). Two thresholds for study inclusion in systematic reviews have been proposed; 55% represents a liberal threshold and 75% represents a conservative threshold. We reported included studies against these thresholds, but due to the shortage of available data, thresholds were not used for study exclusion.

Where additional data were required to determine eligibility for inclusion or to facilitate analysis, the study authors were contacted.

Data Synthesis

If studies were clinical homogenous, then a pooled quantitative synthesis was to be undertaken. As the included studies were clinically heterogeneous, narrative synthesis was used. Data from RCTs and non-randomized studies were not combined for analysis. Data for the second program was analysed separately from that for subsequent programs. Where appropriate, the I^2 statistic was to be used to measure heterogeneity (substantial statistical heterogeneity if I^2 >50%).\textsuperscript{14}

Subgroup Analysis

Pulmonary rehabilitation programs commenced following an exacerbation were to be analysed separately to those commenced in a stable clinical state.

Statistical Analysis

Where data were able to be combined for analysis, data were entered into Review Manager 5 (RevMan Version 5.4: Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen) for calculation of mean differences (MD) and 95% confidence intervals (CI).

Results

Search results

After removal of duplicates, 3036 records were screened, 14 records were reviewed in full text and 10 studies were included (11 reports). Two studies were excluded as data for the subset of participants with COPD were unavailable\textsuperscript{15,16} and one study had no evidence for repeated program\textsuperscript{17} (Figure 1). Meta-analysis was not possible due to study heterogeneity.

Study Characteristics

The 10 included studies collected data between 1996 and 2017. Three studies were undertaken in Australia,\textsuperscript{18-20} two studies were undertaken in Italy\textsuperscript{21,22} and one study each in Turkey,\textsuperscript{23} Canada,\textsuperscript{24} the United Kingdom,\textsuperscript{25} the United States\textsuperscript{26} and France.\textsuperscript{27} Three studies were prospective\textsuperscript{21,22,24} of which two were RCTs\textsuperscript{22,24} (Supplemental Table 3).

One RCT followed participants for 12 months after an initial (inpatient/outpatient) pulmonary rehabilitation program.\textsuperscript{24} Participants were monitored to identify development of an exacerbation and any who experienced such events were subsequently randomized to a repeat program or usual care. The remaining nine studies involved repeat programs during...
periods of clinical stability. Of these, another prospective RCT employed an inpatient pulmonary rehabilitation model delivered twice at 6- and 12-month intervals after the first program or once at 12 months following the first program. Seven studies involved outpatient programs, of which two were published as abstracts (Supplemental Table 4).

Of the eight observational studies, three studies reported outcomes for participants who had undertaken a first and second pulmonary rehabilitation program. Two studies reported outcomes for participants who did and did not repeat programs following the initial program, as well as outcomes for participants following the second and third programs. Three other studies reported outcomes for participants who undertook three and five programs (Supplemental Table 5). Time between the first and subsequent programs in retrospective studies varied from mean 17 (SD 6) months to 45 (24) months (Table 1).

Participant Characteristics
The included studies involved 907 participants with COPD of whom 653 had undertaken more than one pulmonary rehabilitation program (Table 1). The mean age of participants varied from 68 to 70 years, FEV₁ ranged from 36% to

---

**Figure 1 PRISMA flow diagram.**

**Notes:** Adapted from Page M, McKenzie J, Bossuyt P et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

**Abbreviation:** COPD, chronic obstructive pulmonary disease.
58% predicted, and proportion of participants who were female varied from 12% to 64% (RCT: Supplemental Table 5; non-randomized studies: Supplemental Table 6).

### Reported Outcome Measures

The primary outcome measure of health-related quality of life was reported by seven studies, with four studies using the SGRQ\(^{19,21-23}\) and three studies using the CRQ\(^{18,24,25}\) (Table 1).

The secondary outcome measure of exercise capacity was reported by nine studies, with seven studies using the distance walked on the 6-minute walk test (6MWD)\(^{18-20,22,24,26,27}\) two studies using the distance walked on the incremental shuttle walk test (ISWD)\(^{23,25}\) and one study reporting peak workload.\(^{21}\) Hospitalization was reported by three studies\(^{21,22,24}\) and program adherence by two studies.\(^{18,26}\) No studies reported mortality or adverse events (Table 1). Additional data were sought and provided by corresponding authors for two studies\(^{19,23}\) and in two instances original data were available from previous co-author publications.\(^{18,20}\)

### Risk of Bias

Both of the RCTs were assessed as being at high risk of bias, due to the number of domains assessed as unclear (Supplemental Table 7).\(^{22,24}\)

### Table 1 Overview of Time Frame and Reported Outcome Measures

<table>
<thead>
<tr>
<th>Study Design and Setting</th>
<th>Time Between First and Subsequent Programs*</th>
<th>Measure of Health-Related Quality of Life</th>
<th>Measure of Exercise Capacity</th>
<th>Exacerbations and Hospitalizations</th>
<th>Adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized controlled trial: Post exacerbation Carr et al 2009(^{24})</td>
<td>4 (3)</td>
<td>CRQ domains</td>
<td>6MWD</td>
<td>Reported</td>
<td>x</td>
</tr>
<tr>
<td>Randomized controlled trial: Clinical stability, inpatient program Romagnoli et al 2006(^{22})</td>
<td>6 and 12 months</td>
<td>SGRQ total and domains</td>
<td>6MWD</td>
<td>Reported</td>
<td>x</td>
</tr>
<tr>
<td>Non-randomised studies: Clinical stability, inpatient program Al Chikhanie et al 2021(^{27})</td>
<td>10–14 months</td>
<td>x</td>
<td>6MWD</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Non-randomised studies: Clinical stability, outpatient program Atabaki et al 2015(^{26}) Foglio et al 2007(^{21})</td>
<td>45 (24) 17 (6)</td>
<td>x</td>
<td>6MWD</td>
<td>Reported</td>
<td>x</td>
</tr>
<tr>
<td>Heng et al 2014(^{18}) Ingram et al 2014(^{25}) Sandoz et al 2017(^{19})</td>
<td>Median 24 [IQR 13 to 42] 18 (9) 34 (20) second program 29 (15) third program</td>
<td>CRQ domains 6MWD 6MWD, peak workload</td>
<td>x</td>
<td>Reported</td>
<td>x</td>
</tr>
<tr>
<td>Storey et al 2019(^{20}) Yeşiloğlu et al 2018(^{23})</td>
<td>19 (10) 28 (15)</td>
<td>x</td>
<td>6MWD</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

Note: *Data are mean (SD) months between first and second program unless indicated; ^ published abstract; x, not reported.

Abbreviations: CRQ, Chronic Respiratory Disease Questionnaire (score); IQR, interquartile range; ISWD, distance walked on incremental shuttle walk test; 6MWD, distance walked on the 6-minute walk test; SGRQ, St George’s Respiratory Questionnaire (score).
Of the remaining eight non-randomized studies, six studies met the liberal threshold of 55% reflecting a high risk of bias. Four studies that met the conservative threshold of 75% (Supplemental Table 8).

**OUTCOME, Primary: Health-Related Quality of Life**

**RCTs**

In patients recovering from an exacerbation, no overall group × time effect in health-related quality of life was demonstrated comparing those who repeated a program (outpatient program n=7, inpatient n=9) to those who did not (n=17) (post-rehabilitation CRQ domain scores: dyspnea MD 0.4, 95% CI −0.5 to 3; fatigue MD −0.1, 95% CI −0.9 to 0.7; emotional function MD 0.2, 95% CI −0.6 to 1.0; mastery 0.6, 95% CI −0.2 to 1.4; follow-up scores: dyspnea MD 0.8, 95% CI −0.3 to 1.9; fatigue MD 0.5, 95% CI −0.4 to 1.4; emotional function MD 1.0, 95% CI 0.3 to 1.7; mastery MD 1.2, 95% CI 0.5 to 1.9) (Supplemental Figure 1).

In stable patients, one RCT demonstrated significantly better health-related quality of life (SGRQ symptoms domain score MD −9, 95% CI −15 to −3) at 12 months in patients who had repeated pulmonary rehabilitation twice (n=14) compared to those who had repeated once (n=15); no between-group differences were demonstrated in SGRQ total (MD 1, 95% CI −4 to 6) or other domain scores (activity MD 0, 95% CI −7 to 7; impact MD −4 95% CI −10 to 2) (Supplemental Figure 2).

**Non-Randomized Studies**

One abstract (n=125) reported within-group improvements in CRQ total score following the first program (MD 16.4, 95% CI 19.9 to 12.9) and second program (MD 11.1, 95% CI 8.0 to 14.2). The observed improvement was greater following the first program (MD 5.3, 95% CI 0.92 to 9.6). One study demonstrated that first (n=46) and second (n=38) programs results in similar improvements in CRQ domain scores, with more variability demonstrated following the third program (n=6) (Supplemental Figure 3).

Three uncontrolled studies reported SGRQ before and after repeat programs (Figure 2). Clinically significant improvements were demonstrated for repeat programs, however two studies indicated larger gains following the first program when compared to subsequent programs. The proportion of patients attaining a clinically significant change in SGRQ score did not change across the study period: first program n=6 (12.5%); second program n=4 (8.3%); third program n=6 (12.5%); fourth program n=6 (12.5%); and fifth program n=7 (14.6%). Changes in SGRQ domain scores following each program are presented in Supplemental Table 9.

**OUTCOME, Secondary: Exercise Capacity**

**RCTs**

In one RCT of patients recovering from an exacerbation, the difference in 6MWD was greater in those who repeated a program (outpatient program n=7, inpatient n=9) than those who did not (n=17) both immediately post program (MD 30m, 95% CI −36 to 96) and at follow-up (MD 56m (95% CI −21 to 133) (Supplemental Figure 4).

---

**Figure 2** Health-related quality of life in non-randomized studies: Change in St George’s Respiratory Questionnaire total score (3 studies). Data from [19,21,23].

**Notes:** Data are mean difference ± 95% CI. *p < 0.05.

**Abbreviation:** SGRQ, St George’s Respiratory Questionnaire.
In one RCT of stable patients, the difference in 6MWD between those who repeated pulmonary rehabilitation once (n=15) and those who had repeated twice (n=14) was MD 4m (95% CI −58 to 66) at 12 months (Supplemental Figure 5).22

Non-Randomized Studies
Six uncontrolled studies reported 6MWD for repeat programs.18–21,26,27 One study presented the within-program change in 6MWD for the initial program (mean 65m, SD 30, n=190), for the second program (mean 44m, SD 20, n=190) and for the third program (mean 55m, SD 58, n=62).27 Pre/post program 6MWD data are presented in Figure 3 for the remaining studies.18–21,26 All programs resulted in within-program improvements in 6MWD with smaller changes in 6MWD following repeat programs. Six studies reported differences in 6MWD outcomes between first and second programs ranging from no difference to 30 m less improvement on the second program.18–21,26,27 Four studies reported differences in 6MWD outcomes between the first and third programs ranging from 2 to 65 m less improvement on the third program.18,19,21,27 One longitudinal study also reported less improvement in fourth and fifth programs compared to the first program (Supplemental Table 10).21

Data for the proportion of participants who achieved the 6MWD MID following pulmonary rehabilitation programs were reported by five studies (Table 2).18,19,21,26,27 A range of threshold definitions were used. Results for studies using 25–35m thresholds demonstrated consistent results across second programs, with 61–67% of the participants achieving the MID.18,19,21,26,27 One study demonstrated that of the 41/190 non-responders to the initial program, 23 (56%) did respond to the second program and of the 149/190 responders to the initial program, 44 (30%) became non-responders in the second program.27 The study looking at five programs used a 54m threshold and demonstrated consistent results over the first three programs (31–33% achieving the MID) with a decrease evident in the final two programs (first vs fourth program 12.5%, p<0.01; first vs fifth program 14.6%, p=0.03).21

Two abstracts reported change in ISWD.23,25 Clinically significant improvements were demonstrated for repeat programs (MD 46m, 95% CI 9 to 83, n=14; MD 46m, 95% CI 36 to 56, n=125).23,25 Comparisons demonstrated no statistically significant difference between programs in one abstract (p=0.864)23 and a statistically significant decrease in

Figure 3 Exercise capacity in non-randomized studies: Distance walked on the 6-minute walk test (5 studies). Data from [18–21,26].
Notes: Data are mean ± SD. * p < 0.05.
Abbreviation: 6MWD, distance walked on the 6-minute walk test (meters).
change in ISWD following the second program in the other abstract (MD $-18m$, 95% CI $-33$ to $-2$); however, this is less than the MID.28

The study looking at five programs ($n=48$) demonstrated significant improvements in peak workload with each program with the exception of the fifth program (Supplemental Table 11).21 No significant decreases in post-program peak workload comparing the first program with the second program (MD $-1$ watts, 95% CI $-8$ to $6$), third program (MD $-1$ watts, 95% CI $-8$ to $6$), or fourth program (MD $-5$ watts, 95% CI $-12$ to $2$). Comparing the first and fifth programs, a significant decrease in post-program peak workload was demonstrated (MD $-13$ watts, 95% CI $-53$ to $-9$).21

OUTCOME, Secondary: Hospitalizations and Non-Admitted Exacerbations

RCT

In the year following the initial program, there was no difference in the mean number of hospitalizations per participant for those who repeated pulmonary rehabilitation twice (at 6 and 12 months) compared to those who repeated once (at 12 months) (mean 1.0 (SD 0.8) vs 1.5 (1.1) hospitalizations, $p=0.132$).22 Results were similar for hospital length of stay (mean 14 (SD 9) vs 9 (8) days, $p=0.122$).22 Those who repeated once were significantly more likely to spend more than 10 days in hospital ($n=12$) than participants who repeated twice ($n=5$, $p<0.001$).22

Non-Randomized Studies

The study looking at five programs ($n=48$) demonstrated a significant reduction in the number of exacerbations and hospitalizations following repeat programs compared to the year before the first program, as well as a significant increase in the number of participants free from exacerbations and hospitalizations per participant per year (exacerbation: episodes not requiring hospitalization but requiring a change of usual medication and prescription of systemic steroids and/or antibiotics; Supplemental Table 12).21

OUTCOME, Secondary: Adherence

RCT

Nil data.

Non-Randomized Studies

Participants completed a similar number of sessions in the initial and subsequent programs. One study offering a 16-session program reported completion of median 12 (IQR 11 to 14) sessions in the initial program, median 13 (IQR 11 to 14) sessions in the first repeat program and median 14 (IQR 10 to 14) sessions in the second repeat program.18 One study offering a 24-session program reported completion of mean 21 (SD 6) sessions in the initial program and mean 22 (SD 6) sessions in the first repeat program.26

Table 2 Exercise Capacity in Non-Randomized Studies: Proportion of Participants Who Achieved the Minimal Important Difference in the Distance Walked on the 6-Minute Walk Test (5 Studies)

<table>
<thead>
<tr>
<th></th>
<th>Proportion of Participants Who Achieved the 6MWD MID</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Heng et al 2014 (MID ≥ 25m)</td>
</tr>
<tr>
<td>1st program</td>
<td>46/50 (92%)</td>
</tr>
<tr>
<td>2nd program</td>
<td>25/41 (61%)</td>
</tr>
<tr>
<td>3rd program</td>
<td>x</td>
</tr>
<tr>
<td>4th program</td>
<td>x</td>
</tr>
<tr>
<td>5th program</td>
<td>x</td>
</tr>
</tbody>
</table>

Note: Data are n (%); x, not reported.

Abbreviations: m, meters; MID, minimal important difference; 6MWD, distance walked on the 6-minute walk test.
Discussion

Current practice may incorporate repeating pulmonary rehabilitation according to clinical indication and personal factors, but no systematic review of the effects of programs subsequent to an initial pulmonary rehabilitation program has previously been undertaken.

In patients following an exacerbation, a single RCT did not demonstrate any benefits of repeating pulmonary rehabilitation shortly after the exacerbation, in comparison to usual care. For stable patients, clinically meaningful benefits of repeating pulmonary rehabilitation were demonstrated, with one RCT suggesting that more frequent programs might have greater benefit (repeating twice in 12 months vs once in 12 months). Uncontrolled data suggest that the absolute magnitude of improvement in health-related quality of life may not be as large in repeat programs, as it is in the first, but benefits remain clinically meaningful. Important reductions in hospitalizations were also demonstrated with repeating pulmonary rehabilitation. Most studies were at high risk of bias which reduces certainty in these findings.

This review only identified one study that specifically assessed repeat programs following hospitalization. International guidelines recommend referral to pulmonary rehabilitation following an exacerbation, with evidence for improvements in quality of life and exercise capacity as well as important reductions in hospital readmissions and mortality for patients who have had a hospitalization. Recent US data have further demonstrated that initiation of pulmonary rehabilitation within 3 months of hospital discharge was associated with significantly fewer hospital readmissions, shorter hospital stays and a lower mortality risk at 12 months. The well-documented benefits and the value placed on these benefits by people with COPD highlight the need for more evidence to inform this element of COPD management.

The aim of the other recommendation regarding timing for re-referral is to prevent decline in pulmonary rehabilitation outcomes. The data in this review reinforce that clinically important improvements can be achieved following repeat programs, even if the extent of improvement is less than that seen following the initial program. This review also identified important new preliminary evidence that people who were not identified as “responders” following the initial program were able to achieve clinically significant improvements following a second program. One study had previously demonstrated that gains in the CRQ mastery domain were greater following a repeat program relative to the initial program, and suggested that more time may be required to achieve gains, in mastery in this instance, relative to other outcomes. Therefore, patients who are not identified as “responders” following an initial program should be considered eligible for repeat programs.

Participants do not respond uniformly to pulmonary rehabilitation, and the rate of decline in different outcomes following program completion varies. Current guidelines state that re-referral may be considered from 12 months following pulmonary rehabilitation but may be appropriate earlier in the case of clinical indication. Included studies that sought to repeat pulmonary rehabilitation at scheduled intervals following initial programs (6- and 12-months, 12 months, 12 to 18 months) demonstrated benefits for health-related quality of life, consistent proportions of 6MWD responders across the first three programs, and ongoing benefits in terms of reducing both exacerbations and hospitalizations over five programs. Whilst the amount and quality of data preclude firm conclusions, studies in this review do signal that there may be benefits to this approach.

A model of care to assist people with COPD to “maintain the gains” after they finish pulmonary rehabilitation remains elusive but important, particularly as people live for longer with COPD. This review excluded studies providing maintenance programs (ie, exercise training undertaken at a lower dose than the initial program and/or of an indefinite/ongoing nature). International statements and two systematic review have been unable to recommend any model of maintenance due to insufficient evidence of benefit. Despite this, significant clinical resources are devoted to maintenance programs and some patients may find them useful to maintain motivation for physical activity, and to access support from peers and health professionals. The data in this review illustrate the evolving body of evidence for an alternative approach of repeating pulmonary rehabilitation, and supports calls for access to repeat programs. However, resource reallocation would require more evidence not only for clinical measures but also incorporate the impact of repeat programs on outcomes such as healthcare utilization, for which hospitalization forms the bulk of direct medical costs. Reductions in total healthcare costs over 12 months have been associated with pulmonary rehabilitation completion, but...
there are challenges to designing sufficiently large and long prospective studies to capture the long-term data that are required to assess the costs and benefits of repeat programs over many years.

Limitations to this review include the small number of eligible studies; as a result, we elected to include two abstracts, and this represents a variation from our published protocol. The lack of data from prospective studies (total of 62 participants in two RCTs) and the high risk of bias seen in many of the included studies does limit the capacity to draw strong conclusions. Only participants with COPD were included, so the findings may not be extrapolated to other disease groups commonly referred to pulmonary rehabilitation. Included studies mirrored the real-world heterogeneity in pulmonary rehabilitation program format, staffing and resources, but this also precluded meaningful quantitative synthesis.

**Conclusion**
This systematic review provides limited evidence for benefits of repeating pulmonary rehabilitation in people with COPD, including improvements in health-related quality of life and exercise capacity, and reduced need for hospitalization. However, the majority of included studies were at high risk of bias. Future studies should investigate the optimal timing and frequency for repeat programs, and investigate the cost-effectiveness of this strategy.

**Abbreviations**
CI, confidence intervals; COI, conflict of interest; COPD, chronic obstructive pulmonary disease; CRQ, Chronic Respiratory Disease Questionnaire; 6MWD, distance walked on the 6-minute walk test; 6MWT, 6-minute walk test; FER, forced expiratory ratio; FEV₁, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HRQoL, health-related quality of life; IQR, interquartile range; ISWD, distance walked on incremental shuttle walk test; ISWT, incremental shuttle walk test; MD, mean difference; MCID, minimal clinically important difference; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; PROSPERO, Prospective Register of Systematic Reviews; RCTs, randomized controlled trials; SD, standard deviation; SGRQ, St George’s Respiratory Questionnaire.

**Acknowledgments**

**Author Contributions**
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; Have drafted or written, or substantially revised or critically reviewed the article; Have agreed on the journal to which the article will be submitted; Reviewed and agreed on all versions of the article before submission, during revision, the final version accepted for publication, and any significant changes introduced at the proofing stage; Agree to take responsibility and be accountable for the contents of the article.

**Funding**
This work was supported by Institute for Breathing and Sleep Research Grant 2020. The funding body had no role in study design, study conduct or manuscript preparation.

**Disclosure**
The authors report no conflicts of interests in this work.
References


International Journal of Chronic Obstructive Pulmonary Disease 2022:17


